Boehringer Ingelheim Pharma GmbH & Co KG

Boehringer Ingelheim Pharma GmbH & Co KG Pharma Drug Development Products

View Companies with Similar Products

Actilyse® (alteplase) Fibrinolytic treatment of acute myocardial infarction Thrombolytic treatment of acute massive pulmonary embolism

Actilyse® (alteplase) Indicated for thrombolytic treatment in acute ischaemic stroke. is also registered for the indication acute myocardial

Actilyse® Cathflo Indicated for thrombolytic treatment in acute ischaemic stroke. Actilyse® is also registered for the indication acute myocardial

Aggrenox®, Asasantin®Retard (dipyridamole/ASA) Indicated to reduce the risk of stroke in patients who have had transient ischaemia of the brain or

Aptivus® (tipranavir) A non-peptidic protease inhibitor blocks the viral protease, an enzyme needed to complete HIV replication. Aptivus®,

Atrovent® (ipratropium bromide) Indicated as a bronchodilator for maintenance treatment of bronchospasm associated with chronic obstructive pulmonary

Berodual®Bronchodual® Duovent® (fenoterol/ipratropium bromide) For prevention and treatment of symptoms in chronic obstructive airway disorders with

Biopharmaceuticals Boehringer Ingelheim is one of the leading companies for development and manufacture of biopharmaceuticals by offering the entire

Combivent® (ipratropium bromide/salbutamol) Indicated for the management of bronchospasms associated with reversible obstructive airway diseases in

Contract Manufacturing Boehringer Ingelheim BioXcellence™ offers reliable world-class biopharmaceuticals contract manufacturing to the pharmaceutical

Metalyse® (tenecteplase) Fibrinolytic treatment in acute myocardial infarction

Micardis® (telmisartan) Indicated by the US Food and Drug Administration (FDA) for the reduction of the risk of myocardial infarction (heart attack),

Micardis® (telmisartan) An international website, www.micardis.com, provides information on Micardis® and its clinical trial programmes, daily

Mirapex®, Mirapexin®, Sifrol®, Pexola® Mirapex® extended release, Mirapexin® extended release, Sifrol® Retard, Pexola® extended Indicated in the

Mirapexin®, Sifrol®, Pexola®, Mirapex® (pramipexole) Indicated for the symptomatic treatment of moderate to severe idiopathic Restless Legs Syndrome

Pradaxa® (dabigatran etexilate) Dabigatran etexilate, a direct thrombin inhibitor (DTI), is at the forefront of a new generation of oral blood

Process Development Research & development has been the foundation of Boehringer Ingelheim's success and continues to be the major driver of

Small Molecules - APIs and Formulations Boehringer Ingelheim is your development, launch and post-launch partner for your Active Pharmaceutical

Spiriva® (tiotropium) Maintenance treatment of patients with COPD (chronic obstructive pulmonary disease, including chronic bronchitis and emphysema),

Trajenta® Trajenta® (linagliptin) is an inhibitor of the enzyme DPP-4 (dipeptidyl peptidase-4) which is involved in the inactivation of the incretin

Twynsta® (telmisartan + amlodipine) The international website, www.micardis.com, also provides information on Twynsta® and its clinical trial

Viramune® (nevirapine) A non-nucleoside reverse transcriptase inhibitor (NNRTI), indicated for use in combination with other antiretroviral agents for